Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July

Takeda Pharmaceutical and its plasma peers could launch clinical trials in Japan, the US, and Europe as early as July for their unbranded hyperimmune globulin therapy for the treatment of COVID-19. Julie Kim, president of Takeda’s Plasma-Derived Therapies Business Unit,...read more